Technical Analysis for APS - Aptose Biosciences Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | -0.59% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.59% | |
| Bollinger Band Squeeze | Range Contraction | -0.59% | |
| Narrow Range Bar | Range Contraction | -0.59% | |
| BB Squeeze Started | Range Contraction | -0.59% | |
| 20 DMA Resistance | Bearish | -1.75% | |
| Narrow Range Bar | Range Contraction | -1.75% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 2 days ago |
| Rose Above 20 DMA | 2 days ago |
| Up 2% | 2 days ago |
| Up 1% | 2 days ago |
| 20 DMA Resistance | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 2024-05-14
Aptose Biosciences Inc. Description
Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pipe Pipeline Clinic Drug Biotechnology Science Cancer Drugs Biology Genes Chemotherapy Transcription
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.94 |
| 52 Week Low | 0.51 |
| Average Volume | 10,345 |
| 200-Day Moving Average | 3.367 |
| 50-Day Moving Average | 1.919 |
| 20-Day Moving Average | 1.692 |
| 10-Day Moving Average | 1.676 |
| Average True Range | 0.076 |
| RSI (14) | 39.76 |
| ADX | 7.27 |
| +DI | 22.470 |
| -DI | 19.263 |
| Chandelier Exit (Long, 3 ATRs) | 1.801 |
| Chandelier Exit (Short, 3 ATRs) | 1.819 |
| Upper Bollinger Bands | 1.778 |
| Lower Bollinger Band | 1.605 |
| Percent B (%b) | 0.43 |
| BandWidth | 10.263 |
| MACD Line | -0.076 |
| MACD Signal Line | -0.097 |
| MACD Histogram | 0.0209 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.755 | ||||
| Resistance 3 (R3) | 1.763 | 1.747 | 1.743 | ||
| Resistance 2 (R2) | 1.747 | 1.728 | 1.743 | 1.738 | |
| Resistance 1 (R1) | 1.713 | 1.716 | 1.705 | 1.705 | 1.734 |
| Pivot Point | 1.697 | 1.697 | 1.693 | 1.693 | 1.697 |
| Support 1 (S1) | 1.663 | 1.678 | 1.655 | 1.655 | 1.626 |
| Support 2 (S2) | 1.647 | 1.666 | 1.643 | 1.622 | |
| Support 3 (S3) | 1.613 | 1.647 | 1.618 | ||
| Support 4 (S4) | 1.605 |
